O51 Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to <sc>cs</sc>dmards: Summary Results from the 24-Week Phase III RA-Build Study
Rheumatology（2016）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要